Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nicholas Brownstone

Dermatology New York, NY Medical Doctor

NPI 1740643980 CMS profile 9152023

234 E 85Th St, New York, NY 10028

Open in the dashboard

General payments

$14,860

247 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicholas Brownstone of New York, NY is reported in the CMS Open Payments database as having received $14,860 across 247 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,687 113
2024 General $4,999 82
2023 General $2,290 36
2022 General $2,694 14
2021 General $190 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicholas Brownstone
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Nicholas Brownstone were reported at $4,687. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Nicholas Brownstone Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $190 $377 $108–$1,108 $132
2022 $2,694 $514 $143–$1,391 $149
2023 $2,290 $607 $159–$1,674 $160
2024 $4,999 $751 $204–$1,903 $164
2025 $4,687 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $2,438 58 payments
  2. Mindera Corp $2,000 1 payment
  3. AbbVie, Inc. $1,897 61 payments
  4. LEO Pharma Inc. $1,743 31 payments
  5. UCB, Inc. $917 17 payments
  6. Dermavant Sciences, Inc. $713 6 payments
  7. Sun Pharmaceutical Industries Inc. $675 7 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $657 5 payments
  9. Regeneron Healthcare Solutions, Inc. $593 7 payments
  10. Pfizer Inc. $521 7 payments
  11. Other $2,706 47 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,044 237 payments
  2. Consulting Fee $2,000 1 payment
  3. Education $816 9 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $2,530 59 payments
  2. ADBRY $1,378 23 payments
  3. RINVOQ $1,034 41 payments
  4. Bimzelx $794 15 payments
  5. VTAMA $713 6 payments
  6. SKYRIZI Immunology $645 11 payments
  7. SKYRIZI Immunology $630 13 payments
  8. ILUMYA $534 4 payments
  9. DUPIXENT $519 5 payments
  10. STELARA $501 5 payments
  11. Other $4,443 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

776

Median for Dermatology: 534

Drug cost

$1,563,715

Median for Dermatology: $67,151

Branded share of claims

33.9%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 119 $422,824
Tremfya Guselkumab Brand 24 $315,167
Skyrizi Pen Risankizumab-Rzaa Brand 11 $225,600
Humira(Cf) Pen Adalimumab Brand 22 $174,040
Cosentyx Sensoready (2 Pens) Secukinumab Brand 13 $150,702
Rinvoq Upadacitinib Brand 16 $100,494
Adbry Tralokinumab-Ldrm Brand 21 $78,140
Xolair Omalizumab Brand 25 $65,760
Tacrolimus Generic 68 $13,787
Clobetasol Propionate Generic 154 $11,810

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $660
  • Janssen Scientific Affairs, LLC $128
$788 24 —
ADBRY
  • LEO Pharma Inc. $671
$671 21 —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $284
  • GENZYME CORPORATION $172
$456 119 —
VTAMA
  • Dermavant Sciences, Inc. $428
$428 — —
SKYRIZI
  • AbbVie, Inc. $266
$266 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record